# Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin

## TL;DR

This study evaluates a step-by-step method for introducing dapagliflozin to heart failure patients in clinical practice, showing it is effective but highlights challenges in consistent implementation.

## Contribution

The study introduces and evaluates a seven-step systematic approach for implementing dapagliflozin in heart failure treatment.

## Key findings

- 158 out of 191 eligible patients were invited for eligibility discussion, with 69 ultimately prescribed dapagliflozin.
- 60 out of 69 patients persisted on dapagliflozin after 12 months.
- Adverse events and discontinuation reasons included urinary tract infections and hypotension.

## Abstract

To assess a systematic implementation approach for introducing dapagliflozin to individuals with heart failure and reduced ejection fraction in an outpatient clinical setting.

Retrospective medical record data were analysed. All individuals diagnosed with heart failure who resided within the hospital catchment area and had visited cardiology or internal medicine department between 2010 and 2019 were screened by using the main inclusion criteria from the DAPA-HF trial. The effectiveness of the previously described seven-step systematic implementation approach was assessed by the proportion receiving information letter, dapagliflozin treatment, follow-ups at 2–12 weeks and 12 months post-dapagliflozin initiation, persistence on dapagliflozin, adverse events, and reasons for discontinuation.

Of the 2433 individuals, 352 met the main DAPA-HF trial criteria in step 2. After exclusions in steps 3 and 4, 191 individuals remained. Of these, 158 were invited for eligibility discussion in step 5, with 107 having received an information letter beforehand. In step 6, dapagliflozin was prescribed to 69 individuals, and in step 7, follow-ups were conducted with 56 individuals at 2–12 weeks and 62 individuals at 12 months. Sixty out of 69 persisted on dapagliflozin after 12 months. Adverse events were reported by nine individuals. Discontinuation was attributed to reasons such as urinary tract infections, genital or abdominal discomfort, and hypotension.

The systematic introduction of dapagliflozin to heart failure patients was effective. Despite this, challenges in uniformly implementing procedures across patients were evident, emphasizing the necessity for a systematic implementation approach.